GeneHealth - Your precision medicine

Dent Disease

Disease Details

Family Health Simplified

Buy Membership

Description: Dent disease is a rare genetic disorder characterized by defective kidney function, leading to excessive amounts of protein and calcium in the urine.
Type: Dent disease is a rare genetic disorder that primarily affects the kidneys. It is inherited in an X-linked recessive pattern. This means the defective gene responsible for the disease is located on the X chromosome. Since males have one X and one Y chromosome, a single defective gene on their X chromosome will cause the disease. Females, with two X chromosomes, can be carriers if only one of their X chromosomes has the defective gene, but they usually do not show symptoms of the disease.
Signs And Symptoms: Dent's disease often produces the following signs and symptoms:
Extreme thirst combined with dehydration, which leads to frequent urination
Nephrolithiasis (kidney stones)
Hypercalciuria (high urine calcium
Prognosis: Dent disease is a rare genetic disorder that primarily affects the kidneys. The prognosis for individuals with Dent disease can vary. Most patients experience progressive kidney dysfunction leading to chronic kidney disease. While some might develop end-stage renal disease (ESRD) requiring dialysis or kidney transplantation, others may have a more moderate decline in kidney function. Early diagnosis and management can help in delaying the progression of kidney damage, but there is currently no cure for the disease. Regular monitoring and supportive treatments can improve quality of life.
Onset: Dent disease typically manifests during childhood, though symptoms can vary in severity and may not become apparent until later in life. The onset can sometimes be as early as infancy. Early signs often include proteinuria (excess protein in the urine) and can progress to kidney dysfunction over time.
Prevalence: The prevalence of Dent disease, a rare genetic disorder affecting the kidneys, is not precisely known. Due to its rarity and underdiagnosis, specific prevalence data are limited.
Epidemiology: Dent disease is a rare X-linked recessive disorder primarily affecting males. It has an estimated prevalence of roughly 1 in 100,000 to 1 in 200,000 individuals. The disease is characterized by kidney dysfunction, including symptoms like proteinuria, hypercalciuria, nephrocalcinosis, and progressive renal failure. Females can be carriers and may show milder symptoms. The condition results from mutations in the CLCN5 or OCRL gene.
Intractability: Dent disease is currently considered intractable; there is no cure. Management primarily focuses on alleviating symptoms, preventing complications, and maintaining kidney function. Treatment usually involves supportive measures such as maintaining adequate hydration, dietary adjustments, and medications to manage symptoms like hypercalciuria and kidney stones. Regular monitoring by healthcare providers is essential for managing the condition effectively.
Disease Severity: Dent disease is a rare inherited condition affecting the kidneys, characterized by excessive loss of proteins and other substances in the urine.

**Disease Severity:** Dent disease can vary in severity. It often leads to progressive kidney dysfunction, kidney stones, and other complications such as rickets or bone mineralization defects. In severe cases, it can progress to end-stage renal disease, necessitating dialysis or a kidney transplant. Regular monitoring and treatment are crucial to manage symptoms and slow disease progression.
Healthcare Professionals: Disease Ontology ID - DOID:0050699
Pathophysiology: Dent disease is a rare genetic disorder that primarily affects the kidneys. It is characterized by issues in the reabsorption processes in the proximal renal tubules, leading to several urinary abnormalities. Key features include:

**Pathophysiology:**
1. **Genetics**: Dent disease is often caused by mutations in the CLCN5 or OCRL genes.
2. **Proteinuria**: Due to defective endocytosis in the proximal tubules, the filtration barrier function is impaired, leading to loss of low-molecular-weight proteins in urine.
3. **Hypercalciuria**: Excess calcium is excreted in the urine due to defective reabsorption, increasing the risk of kidney stones and nephrocalcinosis.
4. **Aminoaciduria**: Impaired reabsorption of amino acids leads to their excretion in the urine.
5. **Phosphate Wasting**: Defective renal phosphate handling causes hypophosphatemia, leading to bone demineralization and rickets in some cases.
6. **Chronic Kidney Disease**: Progressive renal damage can ultimately lead to chronic kidney disease, necessitating more intensive interventions over time.
Carrier Status: Dent disease is an X-linked recessive disorder primarily affecting the kidneys. Carrier status typically pertains to females, as they can carry one altered copy of the gene (CLC5 or OCRL1) associated with the disease without showing significant symptoms. Males with one altered copy of the gene usually exhibit symptoms of Dent disease. Carrier females may have mild symptoms or may be asymptomatic. If you have further questions about nan in relation to Dent disease, please clarify, as "nan" seems ambiguous in this context.
Mechanism: Dent disease is a rare X-linked recessive disorder that primarily affects the kidneys. It is characterized by low molecular weight proteinuria, hypercalciuria, nephrocalcinosis, and progressive renal failure. The primary molecular mechanisms underlying Dent disease involve mutations in the CLCN5 gene or, less commonly, the OCRL1 gene.

1. **CLCN5 Mutation**:
- The CLCN5 gene encodes a chloride/proton exchanger protein known as ClC-5, which is predominantly expressed in the renal proximal tubules.
- ClC-5 is critical for the proper functioning of endosomes and lysosomes in the proximal tubular cells, particularly for the reabsorption of proteins, ions, and other molecules filtered by the glomerulus.
- Mutations in CLCN5 impair the acidification of endosomes, disrupting the reabsorption process and leading to the excretion of low molecular weight proteins, calcium, and other filtered substances in urine.
- Impaired function of ClC-5 also affects the handling of vitamin D and phosphate metabolism, contributing to various clinical manifestations.

2. **OCRL1 Mutation**:
- The OCRL1 gene encodes an enzyme known as phosphatidylinositol-4,5-bisphosphate 5-phosphatase (OCRL), involved in the phosphoinositide signaling pathway, which is important for intracellular trafficking.
- Mutations in OCRL1, also associated with Lowe syndrome, lead to defective phosphoinositide metabolism, affecting endosomal and lysosomal function.
- In the context of Dent disease, OCRL1 mutations result in similar kidney dysfunctions observed with CLCN5 mutations, disrupting tubular reabsorption and leading to the renal symptoms characteristic of the disease.

Together, mutations in these genes disrupt normal kidney tubular function, leading to the clinical manifestations observed in Dent disease. While ClC-5 is more specifically implicated in the majority of cases, OCRL1 mutations account for a smaller proportion of patients with similar renal phenotypes.
Treatment: As of today, no agreed-upon treatment of Dent's disease is known and no therapy has been formally accepted. Most treatment measures are supportive in nature:

Thiazide diuretics (i.e. hydrochlorothiazide) have been used with success in reducing the calcium output in urine, but they are also known to cause hypokalemia.
In rats with diabetes insipidus, thiazide diuretics inhibit the NaCl cotransporter in the renal distal convoluted tubule, leading indirectly to less water and solutes being delivered to the distal tubule. The impairment of Na transport in the distal convoluted tubule induces natriuresis and water loss, while increasing the reabsorption of calcium in this segment in a manner unrelated to sodium transport.
Amiloride also increases distal tubular calcium reabsorption and has been used as a therapy for idiopathic hypercalciuria.
A combination of 25 mg of chlorthalidone plus 5 mg of amiloride daily led to a substantial reduction in urine calcium in Dent's patients, but urine pH was "significantly higher in patients with Dent's disease than in those with idiopathic hypercalciuria (P < 0.03), and supersaturation for uric acid was consequently lower (P < 0.03)."
For patients with osteomalacia, vitamin D or derivatives have been employed, apparently with success.
Some lab tests on mice with CLC-5-related tubular damage showed a high-citrate diet preserved kidney function and delayed progress of kidney disease.
Compassionate Use Treatment: Dent disease has limited treatment options, and they primarily focus on managing symptoms and slowing progression. For compassionate use or experimental treatments, the following might be considered:

1. **Thiazide Diuretics**: Commonly used to reduce hypercalciuria and stone formation.
2. **ACE Inhibitors or ARBs**: Manage proteinuria and slow kidney damage.
3. **Bicarbonate Supplements**: Correct metabolic acidosis.
4. **Bisphosphonates**: Though primarily used for bone-related conditions, they may be considered due to the presence of rickets or osteomalacia in some Dent disease patients.
5. **Chlorothiazide**: An off-label diuretic option.
6. **Clinical Trials**: Patients may consider participation in ongoing clinical trials investigating novel therapeutic agents for Dent disease.

Always consult with a specialist for personalized advice and to explore eligibility for compassionate use programs or clinical trials.
Lifestyle Recommendations: Lifestyle Recommendations for Dent Disease:

1. **Hydration**: Maintaining adequate hydration to promote kidney function and reduce the risk of kidney stones.
2. **Diet**: A diet low in sodium and protein to lessen the kidney's workload and possibly inhibit kidney stone formation. Monitoring calcium and phosphate intake may also be advised by a healthcare provider.
3. **Regular Monitoring**: Frequent medical check-ups to monitor kidney function, urine protein levels, and assess for complications.
4. **Avoid Nephrotoxic Substances**: Refrain from using medications and substances that could harm the kidneys, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and certain antibiotics.
5. **Physical Activity**: Engage in regular physical activity, but with caution to avoid dehydration and excessive strain.
6. **Manage Blood Pressure**: Keeping blood pressure under control with lifestyle modifications and, if necessary, medications.
7. **Medication Adherence**: Strictly follow prescribed medications, including possible treatments for hypercalciuria, such as thiazide diuretics, as instructed by a healthcare provider.
Medication: Dent disease currently has no specific medication to cure or directly treat the condition. Management focuses on addressing the symptoms and preventing complications. This may include:

1. **Thiazide Diuretics** - To reduce hypercalciuria (excess calcium in urine).
2. **Citrate Supplements** - To prevent kidney stones.
3. **ACE Inhibitors/ARBs** - To manage proteinuria and protect kidney function.
4. **Phosphate Binders and Vitamin D** - For patients with bone disease or to manage levels of phosphate and vitamin D in the body.

Regular monitoring by a healthcare professional is essential to manage the condition effectively and adjust treatments as necessary.
Repurposable Drugs: Current data related to repurposable drugs for Dent disease is limited, as the condition is rare and primarily managed through supportive care. However, medications that have been explored include:

1. **Thiazide diuretics**: These help reduce hypercalciuria and lower the risk of nephrocalcinosis and kidney stones.
2. **ACE inhibitors or ARBs**: Used to manage proteinuria and hypertension.

Continuous research is essential for finding more effective treatments for Dent disease.
Metabolites: Dent disease is a rare genetic disorder affecting the kidneys, specifically causing issues with the reabsorption process in the proximal tubules. Key metabolite abnormalities often associated with Dent disease include:

1. **Hypercalciuria** - Elevated levels of calcium in the urine.
2. **Aminoaciduria** - Increased levels of amino acids in the urine.
3. **Hyperphosphaturia** - Elevated levels of phosphate in the urine.
4. **Low-molecular-weight proteinuria** - Elevated urinary levels of low molecular weight proteins.

These metabolic changes can lead to broader clinical symptoms such as kidney stones, nephrocalcinosis, and progressive renal failure.
Nutraceuticals: Dent disease is a rare genetic disorder that affects the kidneys. Nutraceutical interventions for Dent disease are not well-established due to the rarity and complexity of the condition. Standard treatments primarily focus on managing symptoms and preventing complications, such as kidney stones and chronic kidney disease. A nephrologist may provide dietary recommendations, often including reduced sodium intake and increased water consumption, to help manage the disease.

Regarding nanotechnology, its application in Dent disease is still largely in the research phase. Nanotechnology offers potential for targeted drug delivery and improved diagnostic techniques but is not currently part of standard treatment protocols. Ongoing research aims to explore how nanotechnology could be used to develop better therapies for various kidney disorders, including Dent disease.
Peptides: Dent disease is a rare genetic disorder that primarily affects the kidneys, causing proteinuria, hypercalciuria, nephrocalcinosis, and progressive renal failure. Molecular therapies such as peptides are not currently standard treatments for Dent disease. Research is ongoing to explore various therapeutic approaches, but as of now, managing symptoms primarily involves addressing the complications of kidney dysfunction, like using medications to control proteinuria and hypercalciuria.

"Nan" does not appear to relate directly to Dent disease. If "nan" refers to nanoparticles, this technology is still in the experimental stage for many renal conditions, including Dent disease. The application of nanoparticles for drug delivery or genetic therapy holds potential, but more research is needed to establish effective treatments for Dent disease involving nanotechnology.